On Feb. 18, the patent for Lundbeck's Northera officially expired in the US, after which companies are lining up to bite into the market, which the Danish pharmaceutical giant has exclusive rights to up until now.
12 companies, including Teva's generics business and Indian Lupin, have received approvals for their respective copies of the product with the name droxidopa.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.